ACP
LRMR icon

Acuta Capital Partners’s Larimar Therapeutics LRMR Stock Holding History

Acuta Capital Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-863,100
Closed -$18.5M – 53
2020
Q4 		$18.5M Buy
863,100
+33,100
+4% +$663K 5.03% 4
2020
Q3 		$12.6M Buy
830,000
+6,831
+0.8% +$86.5K 3.42% 7
2020
Q2 		$10.3M Buy
823,169
+707,669
+613% +$8.24M 2.97% 11
2020
Q1 		$1.07M Buy
115,500
+32,167
+39% +$423K 0.52% 29
2019
Q4 		$1.11M Buy
+83,333
New +$796K 0.27% 37
2018
Q3 		– Sell
-20,833
Closed -$2.56M – 42
2018
Q2 		$2.56M Buy
+20,833
New +$1.77M 0.46% 35
2015
Q4 		– Sell
-4,293
Closed -$1.65M – 63
2015
Q3 		$1.65M Sell
4,293
-115
-3% -$51.8K 0.95% 35
2015
Q2 		$1.83M Sell
4,408
-3,925
-47% -$1.64M 1.13% 27
2015
Q1 		$3.96M Sell
8,333
-22
-0.3% -$10.4K 3.34% 8
2014
Q4 		$3.09M Buy
+8,355
New +$2.15M 2.09% 10

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Acuta Capital Partners's LRMR Position: Q1 2021 in Review

Acuta Capital Partners sold out of Larimar Therapeutics (LRMR) in Q1 2021, closing a stake of 863,100 shares — an estimated $18.5M sold.

Acuta Capital Partners first reported a position in LRMR in Q4 2014 and held it in 10 quarters. The position peaked at $18.5M in Q4 2020. 57 funds tracked by Wall St. Rank hold LRMR as of Q1 2021.

  • Acuta Capital Partners reported no remaining Larimar Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 863,100 Larimar Therapeutics shares in Q1 2021, an estimated $18.5M.
  • Acuta Capital Partners first reported a position in Larimar Therapeutics in Q4 2014 and held it in 10 quarters.
  • Acuta Capital Partners's Larimar Therapeutics position peaked at $18.5M in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2021.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.